Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2006 2
2008 1
2009 1
2010 1
2012 1
2014 2
2015 2
2016 1
2017 1
2018 3
2019 3
2020 6
2021 4
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Microsatellite Stable Ovarian Carcinoma"
Page 1
Elucidation of genomic origin of synchronous endometrial and ovarian cancer (SEO) by genomic and microsatellite analysis.
Sakamoto I, Hirotsu Y, Amemiya K, Nozaki T, Mochizuki H, Omata M. Sakamoto I, et al. J Gynecol Oncol. 2023 Jan;34(1):e6. doi: 10.3802/jgo.2023.34.e6. Epub 2022 Oct 6. J Gynecol Oncol. 2023. PMID: 36245225 Free PMC article. Review.
OBJECTIVE: Elucidation of clonal origin of synchronous endometrial and ovarian cancers (SEOs). METHODS: We reviewed 852 patients who diagnosed endometrial and/or ovarian cancer. ...Four out of 17 (24%) SEOs had mismatch repair (MMR) protein deficiency and MSI-high ( …
OBJECTIVE: Elucidation of clonal origin of synchronous endometrial and ovarian cancers (SEOs). METHODS: We reviewed 852 patients who …
PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.
Sokol ES, Jin DX, Fine A, Trabucco SE, Maund S, Frampton G, Molinero L, Antonarakis ES. Sokol ES, et al. JCO Precis Oncol. 2022 Jun;6:e2100531. doi: 10.1200/PO.21.00531. JCO Precis Oncol. 2022. PMID: 35772050 Free PMC article.
Although MSI-H samples had a higher BRCAm prevalence relative to microsatellite-stable tumors, these BRCA1/2 mutations were generally monoallelic and were not associated with elevated gLOH. Our findings suggest that most BRCAm coexisting with microsatellite i …
Although MSI-H samples had a higher BRCAm prevalence relative to microsatellite-stable tumors, these BRCA1/2 mutations were ge …
Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma.
Li L, Yue P, Song Q, Yen TT, Asaka S, Wang TL, Beavis AL, Fader AN, Jiao Y, Yuan G, Shih IM, Song Y. Li L, et al. J Pathol. 2021 Jan;253(1):119-128. doi: 10.1002/path.5566. Epub 2020 Nov 13. J Pathol. 2021. PMID: 33016334
The percentage of common mutations between AH lesions and corresponding ECs varied significantly, ranging from 0.1% to 82%. Microsatellite stable AHs had fewer cancer driver mutations than ECs (5 versus 7, p = 0.017), but among microsatellite unstable AHs and …
The percentage of common mutations between AH lesions and corresponding ECs varied significantly, ranging from 0.1% to 82%. Microsatellit …
Chromatin organisation and cancer prognosis: a pan-cancer study.
Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE. Kleppe A, et al. Lancet Oncol. 2018 Mar;19(3):356-369. doi: 10.1016/S1470-2045(17)30899-9. Epub 2018 Feb 3. Lancet Oncol. 2018. PMID: 29402700 Free PMC article.
The resulting marker of chromatin heterogeneity, termed Nucleotyping, was subsequently independently validated in six patient cohorts: 442 patients with stage I or II colorectal cancer in the Gloucester Colorectal Cancer Study (UK); 391 patients with stage II colorectal cancer in …
The resulting marker of chromatin heterogeneity, termed Nucleotyping, was subsequently independently validated in six patient cohorts: 442 p …
Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI, Killian JK, Venstrom JM, Ramkissoon SH, Ross JS, Elvin JA. Lin DI, et al. Mod Pathol. 2021 May;34(5):983-993. doi: 10.1038/s41379-020-00699-1. Epub 2020 Oct 19. Mod Pathol. 2021. PMID: 33077920 Free article.
Malignant Brenner tumor is a rare primary ovarian carcinoma subtype that may present diagnostic and therapeutic conundrums. ...FGFR3-mutated cases had an associated benign or borderline Brenner tumor pre-cursor components, further confirming the diagnosis and the …
Malignant Brenner tumor is a rare primary ovarian carcinoma subtype that may present diagnostic and therapeutic conundrums. .. …
Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma.
Chapel DB, Patil SA, Plagov A, Puranik R, Mendybaeva A, Steinhardt G, Wanjari P, Lastra RR, Kadri S, Segal JP, Ritterhouse LL. Chapel DB, et al. Mod Pathol. 2019 Oct;32(10):1508-1520. doi: 10.1038/s41379-019-0298-5. Epub 2019 Jun 11. Mod Pathol. 2019. PMID: 31186530 Free article.
Out of nine microsatellite-stable atypical hyperplasia/endometrial intraepithelial neoplasia specimens, four showed mismatch repair loss by immunohistochemistry. All atypical hyperplasia/endometrial intraepithelial neoplasia and endometrial carcinoma specimen …
Out of nine microsatellite-stable atypical hyperplasia/endometrial intraepithelial neoplasia specimens, four showed mismatch r …
Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma.
Rosen DG, Cai KQ, Luthra R, Liu J. Rosen DG, et al. Mod Pathol. 2006 Nov;19(11):1414-20. doi: 10.1038/modpathol.3800672. Epub 2006 Aug 25. Mod Pathol. 2006. PMID: 16941012 Free article.
However, it is unclear whether immunohistochemical staining can accurately predict microsatellite instability status. We sought here to evaluate the sensitivity, specificity, and predictive values of immunostaining for the expression of the DNA mismatch-repair genes hMLH1 …
However, it is unclear whether immunohistochemical staining can accurately predict microsatellite instability status. We sought here …
Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer.
Stasenko M, Feit N, Lee SSK, Shepherd C, Soslow RA, Cadoo KA, Alektiar K, Da Silva EM, Martins Sebastião AP, Leitao MM Jr, Gardner G, Selenica P, Abu-Rustum NR, Weigelt B, Mueller JJ. Stasenko M, et al. Int J Gynecol Cancer. 2020 Jun;30(6):717-723. doi: 10.1136/ijgc-2020-001241. Epub 2020 May 5. Int J Gynecol Cancer. 2020. PMID: 32376737 Free PMC article.
Tumor-normal profiling using massively parallel sequencing targeting 468 genes was performed. Microsatellite instability was assessed using MSIsensor. DNA mismatch repair (MMR) protein proficiency was determined by immunohistochemistry. ...Primary tumors of 9 recurrent and …
Tumor-normal profiling using massively parallel sequencing targeting 468 genes was performed. Microsatellite instability was assessed …
Microsatellite instability and ploidy status define three categories with distinctive prognostic impact in endometrioid endometrial cancer.
Bilbao-Sieyro C, Ramírez R, Rodríguez-González G, Falcón O, León L, Torres S, Fernández L, Alonso S, Díaz-Chico N, Perucho M, Díaz-Chico JC. Bilbao-Sieyro C, et al. Oncotarget. 2014 Aug 15;5(15):6206-17. doi: 10.18632/oncotarget.2187. Oncotarget. 2014. PMID: 25026289 Free PMC article.
Microsatellite instability (MSI) and aneuploidy are inversely related phenomena. ...All MSI tumors (23%) were scored as diploid, and 14% of microsatellite stable (MSS) tumors presented aneuploidy. MSI tumors associated with older age at diagnosis, non-obesity …
Microsatellite instability (MSI) and aneuploidy are inversely related phenomena. ...All MSI tumors (23%) were scored as diploid, and …
The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
Sorscher S. Sorscher S. Oncologist. 2018 Nov;23(11):1266-1268. doi: 10.1634/theoncologist.2017-0681. Epub 2018 Jun 4. Oncologist. 2018. PMID: 29866945 Free PMC article.
For example, the FDA-approved use of the PARP inhibitor olaparib is for ovarian or breast cancers in patients harboring a BRCA germline mutation [N Engl J Med 2012;366:1382-1392, N Eng J Med 2017;377:523-533]. ...Cancers resulting from the germline MMR gene mutation as the …
For example, the FDA-approved use of the PARP inhibitor olaparib is for ovarian or breast cancers in patients harboring a BRCA germli …
27 results